Clinical Trial Update: Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia [Phase 3]

View source ↗

Summary

Phase 3 trial assessing ranibizumab for visual impairment due to choroidal neovascularization from pathologic myopia; completed with results posted in 2013, eva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pathological Myopia

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pathological Myopia | Phase 3 | Status: COMPLETED | Results posted: 2013-10-18